Trial reportJournal of Crohn's & colitis2026
2'-Fucosyllactose modulates gut microbiota and systemic metabolism in mild-to-moderate ulcerative colitis: a randomized crossover trial.
Trial report in Journal of Crohn's & colitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06050811 (A Randomised, Placebo-controlled, Double-blinded Crossover Trial Investigating the Effect of a Dietary Prebiotic on Clinical, Metabonomic, Microbiological, and Immunological Outcomes in Patients With Mild to Moderate Ulcerative Colitis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised, Placebo-controlled, Double-blinded Crossover Trial Investigating the Effect of a Dietary Prebiotic on Clinical, Metabonomic, Microbiological, and Immunological Outcomes in Patients With Mild to Moderate Ulcerative Colitis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND AND
aimsThe gut microbiota in active ulcerative colitis (UC) differs from that of healthy individuals. Human milk oligosaccharides (HMOs) are prebiotics found in human breastmilk which promote infant health, but are lesser studied in adults. The objective of this study was to assess the impact of the HMO 2'-fucosyllactose (2'-FL) on symptoms, inflammation, gut microbiota, and systemic metabolism in mild-to-moderate UC.
methodsIn this randomized, double-blind, placebo-controlled crossover clinical trial, 38 patients with mild-to-moderate UC were randomized to receive 28 days of 2'-FL or 28 days of maltodextrin placebo, followed by washout and crossover. Patient-reported outcome measures, feces, urine, and serum samples were collected before and after each intervention, and after a final washout period.
resultsAlthough no clear treatment effect was observed on conventional clinical indices, 2'-FL exposure was associated with improved patient-reported disease control. 2'-FL significantly modulated the gut microbiota, markedly increasing Bifidobacterium abundance (effect size 4.4%, 95% CI 2.33%-6.47%, P = 6.5 × 10-5). Fecal metabolite profiles showed changes consistent with altered microbial carbohydrate metabolism. Exploratory analyses suggested that age and baseline microbiota may influence clinical and biological responsiveness to 2'-FL.
conclusions2'-FL exposure was associated with improvement in patient-reported disease control, gut microbiota modulation, and cross-compartmental host-microbial metabolic profile modifications; Clinicaltrials.gov number, NCT06050811.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.